Essay answer on sinonasal undifferentiated carcinoma

Reading File

Finding Sources

Searching PubMed

"sinonasal undifferentiated carcinoma"

Reading File

Reading Article

Finding Sources

Reading File

Finding Sources

Reading File

I now have comprehensive material. Let me write the essay.

Sinonasal Undifferentiated Carcinoma (SNUC)

Introduction

Sinonasal undifferentiated carcinoma (SNUC) is a rare, highly aggressive malignant epithelial neoplasm of the nasal cavity and paranasal sinuses. It was first recognised as a distinct clinicopathological entity by Mills and colleagues in 1987 and is defined by the absence of squamous, glandular, or neuroendocrine differentiation on light microscopy. Because of its rarity, most clinical data derive from retrospective series spanning decades and small institutional cohorts. Despite multimodal treatment advances, SNUC carries one of the worst prognoses among all sinonasal malignancies.

Epidemiology and Aetiology

SNUC is exceedingly rare, accounting for fewer than 5% of all sinonasal malignancies. It shows a male predominance (approximately 2:1) and most commonly presents in the fifth to sixth decade of life. Unlike sinonasal squamous cell carcinoma (SCC), there is no established causative link with occupational exposures (e.g., nickel, chromium, hardwood dust), tobacco, or EBV infection. The aetiology remains largely unknown.

Recent genomic studies have substantially reshaped the classification of undifferentiated sinonasal tumours. Several molecularly distinct entities — previously grouped under the SNUC umbrella — have been delineated, including:

IDH2-mutant SNUC — carries somatic IDH2 hotspot mutations and a distinctive histomorphology
SMARCA4-deficient (INI-1-deficient) sinonasal carcinoma — loss of SWI/SNF chromatin remodelling complex subunit
NUT (nuclear protein in testis) midline carcinoma — defined by NUT gene rearrangement, extremely aggressive
SMARCB1-deficient sinonasal carcinoma

This means that historical series may actually describe heterogeneous tumour populations, complicating interpretation of outcomes data. Modern pathological re-review with molecular profiling is therefore essential — Cummings Otolaryngology Head and Neck Surgery explicitly notes that retrospective series "often span decades" and, without re-review, "may describe multiple distinct tumour types."

Pathology

Gross Features

Tumours are bulky, fleshy masses that are locally destructive and frequently involve multiple sinonasal subsites simultaneously at presentation. The nasal cavity, ethmoid sinuses, and maxillary sinuses are the most common primary sites.

Histology

SNUC is composed of small round blue cells arranged in nests, sheets, trabeculae, or ribbons with prominent necrosis and high mitotic activity. There is no squamous pearl formation, mucin production, or Homer Wright rosette formation. Pleomorphism is moderate to marked.

Immunohistochemistry (IHC)

The IHC profile distinguishes SNUC from related small round cell tumours:

Marker	SNUC	ENB	SNEC
Cytokeratin (CK)	Positive	Negative	Positive
EMA	Positive	Focal	Positive
NSE	Weak positive	Positive	Positive
Chromogranin/Synaptophysin	Negative	Strongly positive	Positive (diffuse)
S100	Negative	Positive (sustentacular)	Variable
p63/p40	Negative	Negative	Negative

— K.J. Lee's Essential Otolaryngology

SNUC is thus characterised as CK+, EMA+, weakly NSE+, and negative for neuroendocrine markers (chromogranin, synaptophysin). This profile is critical to separate it from esthesioneuroblastoma (ENB) and sinonasal neuroendocrine carcinoma (SNEC).

Differential Diagnosis

The main entities to exclude are:

Esthesioneuroblastoma (ENB) — CK negative, S100-positive sustentacular cells, Homer Wright rosettes
Sinonasal neuroendocrine carcinoma (SNEC) — CK positive but diffusely expresses neuroendocrine markers
NUT carcinoma — requires FISH or IHC for NUT protein; extremely aggressive
Lymphoma — CD45+, CK negative
Rhabdomyosarcoma — desmin, myogenin positive
Mucosal melanoma — HMB-45, Melan-A, S100 positive
Nasopharyngeal carcinoma (NPC) — EBV-encoded RNA (EBER) in situ hybridisation positive; frequently involves the nasopharynx

A 2024 review by Tandon & Kakkar (Surg Pathol Clin, PMID 39489553) emphasises that "histologic features overlap with each other and with other sinonasal neoplasms," and that IHC, in situ hybridisation, and molecular testing are all necessary to arrive at a final diagnosis.

Clinical Features

SNUC typically presents at an advanced stage (80% are T4 at presentation per meta-analysis data). Symptoms are non-specific and include:

Unilateral nasal obstruction and epistaxis (most common)
Facial pain and swelling
Proptosis, diplopia, epiphora — orbital involvement
Trismus — pterygoid/infratemporal involvement
Cranial nerve palsies — skull base involvement (CN II, V, VI)
Headache — intracranial extension

Because these symptoms overlap with chronic sinusitis, diagnosis is frequently delayed.

Staging

SNUC is staged using the AJCC/UICC TNM staging system for paranasal sinus or nasal cavity primaries, depending on the site of origin. The majority of patients present with T4 disease (erosion of skull base, orbit, pterygoid plates, anterior cranial fossa, or dura):

T1 — confined to one subsite of the nasal cavity/paranasal sinus, without bony erosion
T2 — extension to adjacent subsite or adjacent region
T3 — extension to medial orbital floor/wall, maxillary sinus, palate, cribriform plate
T4a — anterior skull base, orbital contents, pterygoid plates, frontal/sphenoid sinuses (moderately advanced)
T4b — orbital apex, dura, brain, CN involvement (very advanced)

Regional (cervical) nodal involvement is seen in 10–30% at presentation, and distant metastases (lungs, bone, liver) are common.

Imaging

CT

CT is essential for delineating bony destruction. Findings typically show an aggressive soft-tissue mass with extensive bone erosion across multiple sinuses, commonly involving the skull base.

MRI

MRI is superior for assessing soft-tissue extent — orbital, dural, and brain invasion. SNUC typically shows:

Intermediate T1 signal
Intermediate-to-low T2 signal (hypercellular tumour)
Avid heterogeneous enhancement
Restricted diffusion on DWI (high cellularity → low apparent diffusion coefficient / ADC)

Cummings Otolaryngology notes that ADC on DWI is useful in characterising sinonasal neoplasms; highly cellular malignant tumours like SNUC show low ADC values.

PET-CT

PET-CT is valuable for staging regional nodes (including retropharyngeal nodes), detecting occult distant metastases, and assessing treatment response.

Management

Given the rarity of SNUC, there are no prospective randomised trials. Management is based on retrospective series, institutional protocols, and meta-analyses, and should always occur in a multidisciplinary setting.

Surgery

Complete gross surgical resection confers the best local control. In a UCSF series, 5-year local control was 74% for gross total resection vs. 24% for subtotal resection — a stark difference underscoring the importance of achieving negative margins (Cummings Otolaryngology Head and Neck Surgery).

Surgical approaches include:

Craniofacial resection (CFR) — the historical gold standard; combined transfacial + frontal craniotomy allows en-bloc resection of the skull base and dura, with pericranial flap reconstruction. Mortality ~4.7%, morbidity 33–36%
Endoscopic endonasal approach (EEA) — now increasingly used; avoids facial incisions and craniotomy, offers excellent magnification. Suitable for select cases without significant orbital or lateral skull base extension

Radiation Therapy

Radiation forms an essential component of treatment. IMRT is the standard technique, allowing conformal high-dose delivery while sparing adjacent structures (optic apparatus, brainstem, temporal lobes).

Proton beam therapy offers a dosimetric advantage in skull base lesions by reducing integral dose to surrounding critical structures, though survival equivalence over IMRT is not definitively established for SNUC.

Chemotherapy

SNUC is chemosensitive. Platinum-based regimens (cisplatin ± 5-fluorouracil; or cisplatin + etoposide) are used in:

Induction (neoadjuvant) chemotherapy — followed by concurrent chemoradiation or surgery
Concurrent chemoradiation — for unresectable disease or organ preservation

A landmark 2024 meta-analysis by Burggraf et al. (Head Neck, PMID 39162231) — analysing 192 patients with individual patient data — demonstrated 5-year OS of 72.6% in patients receiving induction chemotherapy vs. 44.5% without induction chemotherapy, concluding that "IC should be considered in every patient diagnosed with SNUC."

Trimodality Therapy

Multiple studies support trimodality therapy (induction chemotherapy + chemoradiation + surgery) as the most effective approach:

Rischin et al. reported 2-year OS of 64% with induction platinum/5-FU followed by concurrent platinum-based chemoRT
Rosenthal et al. (MD Anderson) reported 5-year OS of 64.2% with combination therapy
Mourad et al. (18 patients) found improved local control and freedom from distant metastasis with trimodality vs. single/dual modality
Morand et al. meta-analysis (29 series, 390 patients): single modality was associated with nearly 3-fold increased risk of death (HR 2.97 vs. dual modality; HR 2.80 vs. triple modality). Best outcomes with surgery + radiation.

The optimal sequencing (induction → CRT → surgery vs. upfront surgery → adjuvant CRT) remains debated and is influenced by resectability and patient performance status.

Neck Management

Elective neck treatment is warranted even in clinically N0 patients given the significant risk of regional failure. The Morand meta-analysis found 27% of patients experienced regional failure at 2 years. Elective neck irradiation (to ~50 Gy equivalent) is generally incorporated into radiotherapy planning.

Prognosis

SNUC carries a dismal prognosis when treated with single-modality therapy:

An international collaborative study of 344 patients reported 5-year OS of 0% for undifferentiated tumours (n=14)
The University of Michigan experience: 5-year OS of 22%
With aggressive multimodal treatment, 5-year OS approaches 44–65% in modern series
Burggraf et al. 2024 meta-analysis: pooled 5-year OS of 43.8% across 13 studies

Principal modes of failure are:

Locoregional recurrence — especially in incompletely resected or unresected disease
Distant metastases — lungs, bone, liver; common even after local control

Adverse prognostic factors include advanced T stage, skull base/dural invasion, nodal metastasis, incomplete resection, and absence of chemotherapy.

Special Considerations: Molecular Subtypes and IDH2

The recognition of IDH2-mutant SNUC is clinically important: IDH2 mutations are targetable with inhibitors (e.g., enasidenib). These tumours may have a more favourable biology. Molecular profiling of all newly diagnosed SNUC cases is increasingly recommended to identify actionable alterations and to enable correct diagnosis within the spectrum of sinonasal undifferentiated/poorly differentiated carcinomas.

Summary

SNUC is a rare, highly lethal sinonasal malignancy characterised by:

Presentation at advanced stage with extensive local destruction and high distant metastasis risk
Small round blue cell histology; CK+, EMA+, neuroendocrine marker negative
Mandatory exclusion of ENB, SNEC, NUT carcinoma, and other small round cell tumours via IHC and molecular testing
Treatment with multimodal therapy — induction chemotherapy is strongly supported by the 2024 meta-analysis as improving survival
5-year OS of ~44–73% with modern multimodal approaches, versus near-zero with single-modality treatment
Emerging molecular classification (IDH2, SMARCA4, NUT gene rearrangement) reshaping nosology and opening targeted therapy avenues

Key References:

Cummings Otolaryngology Head and Neck Surgery (pp. 2277–2278, Skull Base chapter)
K.J. Lee's Essential Otolaryngology (10th ed., pp. 593, 599)
Burggraf M et al. Head Neck. 2024 — Meta-analysis; IC significantly improves 5-year OS (72.6% vs. 44.5%) [PMID: 39162231]
Tandon A, Kakkar A. Surg Pathol Clin. 2024 — Molecular classification update [PMID: 39489553]

Can you please make this into pdf

Reading File

Running Command

Writing File

Running Command

Your PDF is ready:

SNUC Essay

PDF Document · PDF

The document includes all sections from the essay — introduction, epidemiology, pathology (with the IHC comparison table), clinical features, staging (with TNM table), imaging, management, prognosis (with outcomes table), molecular subtypes, summary, and references — formatted with a clean two-tone header style, section dividers, and proper A4 layout.

Explain in detail surgical management of nose and pns tumors , surgical technique used for different tnm stages of maxilla , ethmoid and nasal cavity

Reading File

Finding Sources

Reading File

Finding Sources

Reading File

Finding Sources

Reading File

I now have comprehensive material. Let me compile the full detailed essay.

Surgical Management of Nose and Paranasal Sinus Tumours: Techniques by TNM Stage

I. Overview and Principles

The primary treatment goal for sinonasal malignancies is complete surgical resection with negative margins. This principle underpins all decisions, regardless of approach. Surgery is typically combined with postoperative radiotherapy (and increasingly chemotherapy), forming the cornerstone of curative treatment.

The type of procedure selected depends on:

Tumour location and subsite (maxillary sinus, nasal cavity, ethmoid, frontal, sphenoid)
T-stage — specifically, invasion of adjacent subsites and vital structures
Histology (SCC, adenocarcinoma, SNUC, olfactory neuroblastoma, etc.)
Surgeon experience and institutional capacity

A critical anatomical landmark is Ohngren's line — an imaginary plane from the medial canthus to the angle of the jaw. Infrastructural lesions (anterior/inferior to the line) present earlier and are more likely to be completely resected. Suprastructural lesions (posterior/superior) more frequently involve the orbit, skull base, infratemporal fossa, and carotid artery, conferring a markedly worse prognosis.

II. AJCC TNM Staging (8th Edition) — Maxillary Sinus

T Stage	Criteria
T1	Tumour limited to maxillary sinus mucosa, no bony erosion or destruction
T2	Tumour causing bone erosion/destruction including extension to hard palate and/or middle nasal meatus, except posterior wall of maxillary sinus and pterygoid plates
T3	Tumour invades any of: posterior wall of maxillary sinus, subcutaneous tissues, floor or medial wall of orbit, pterygoid fossa, ethmoid sinuses
T4a	Moderately advanced: invades anterior orbital contents, skin of cheek, pterygoid plates, infratemporal fossa, cribriform plate, sphenoid or frontal sinuses
T4b	Very advanced: invades orbital apex, dura, brain, middle cranial fossa, cranial nerves other than V2, nasopharynx, or clivus

III. AJCC TNM Staging (8th Edition) — Nasal Cavity and Ethmoid Sinus

T Stage	Criteria
T1	Tumour restricted to any one subsite, with or without bony invasion
T2	Tumour invades two subsites in a single region or extends to an adjacent region within the nasoethmoid complex, with or without bony invasion
T3	Tumour extends to medial orbital wall/floor, maxillary sinus, palate, or cribriform plate
T4a	Moderately advanced: invades anterior orbital contents, skin of nose or cheek, anterior cranial fossa (minimal extension), pterygoid plates, sphenoid or frontal sinuses
T4b	Very advanced: orbital apex, dura, brain, middle cranial fossa, cranial nerves other than V2, nasopharynx, or clivus

IV. Preoperative Assessment

Before any surgical intervention, the following are mandatory:

Biopsy — Transnasal biopsy is the first step. Prior to biopsy, MRI must exclude an encephalocele or highly vascular tumour (e.g., juvenile nasopharyngeal angiofibroma). Biopsy should not violate surgical planes — avoid Caldwell-Luc approaches for biopsy as they may contaminate soft tissue planes in the cheek.
CT scan — Defines bony architecture, extent of erosion, and lymph node metastases.
MRI — Superior for soft tissue invasion, orbital, dural, and brain involvement; perineural invasion along V2/V3; medullary bone involvement.
PET-CT — For detecting distant metastases and occult nodal disease (retropharyngeal nodes). Note: sinonasal inflammation can cause false-positive FDG uptake.
Multidisciplinary tumour board review before treatment initiation.
Dental evaluation and prosthodontic planning — Prefabricated obturators must be prepared before maxillectomy; gastrostomy tube consultation for nutritional support.

V. Surgical Approaches: Principles

Open vs. Endoscopic

Feature	Open	Endoscopic
Exposure	Superior; en bloc resection	High-definition magnified view; no craniofacial dissection
Best for	Advanced disease, lateral/orbital/skull base extension	Medial, superior, endoluminal disease without soft tissue extension
Limitations	Cosmetic morbidity; facial incisions; retraction injury	Not suited for facial/orbital soft tissue extension, palatal involvement, dural involvement beyond mid-pupillary line
Principle	Strict oncologic margins	Strict oncologic margins

VI. Surgical Techniques by Approach

A. Caldwell-Luc (Sublabial) Approach

Indications: Small, limited infrastructural malignancies — upper alveolar ridge, anterior nasal cavity, hard palate, anterolateral maxillary sinus.

Technique:

Incision through ipsilateral gingivobuccal mucosa, leaving an inferior cuff for closure
Can be extended bilaterally for a degloving approach
Provides access to the anterior maxillary wall
An obturator is prefabricated if entry into the maxillary sinus is anticipated
For limited alveolar ridge lesions, an alveolectomy is performed with a prefabricated denture

B. Lateral Rhinotomy

Indications: Lesions not involving the orbit or palate — nasal cavity, medial maxillary wall, ethmoid sinuses.

Technique:

Incision begins at the philtrum above the lip, across the nasal floor, around the lateral nasal ala, then along the nasal sidewall junction to the medial canthus
A modified variation hugs the lateral alar groove and travels up the medial sidewall to reduce alar distortion and ectropion
Extensions depending on disease extent:
- Lynch extension (up to medial eyebrow): medial orbital wall, lacrimal apparatus
- Subciliary extension (lateral along lower eyelid crease to zygoma): orbital floor access
- Weber-Ferguson incision (incorporates an upper lip split): enhanced inferior access to palate for total maxillectomy

C. Medial Maxillectomy

Indications: Lesions involving the entire lateral nasal wall, not extending to: orbit, anterior cranial fossa, lateral maxilla, or alveolus. Typically T1–T2 nasal cavity/ethmoid tumours.

Resection includes: Middle and inferior turbinates, contents of ethmoid and maxillary sinuses, and the entire medial maxillary wall.

Technique (open):

Extended lateral rhinotomy incision; upper cheek flap raised
Anterior maxillary sinus wall burred out for exposure
Medial wall periosteum incised and elevated off orbital rim and lamina papyracea
Medial canthal ligament transected and tagged for reattachment
Lacrimal sac and duct elevated; duct transected flush at the orbital rim
Anterior and posterior ethmoid arteries identified and ligated
Curved osteotome frees the medial maxillary wall parallel to the nasal floor
Posterior attachment divided near the choanae with angled scissors
Nasolacrimal duct stented at closure; medial canthal ligament resutured to nasal bone; meticulous two-layer closure

D. Infrastructural Maxillectomy

Indications: T2 maxillary sinus lesions — tumours of the hard palate, alveolar ridge, and inferior maxillary sinus not reaching the orbital floor.

Resection: Dentition + alveolar ridge + hard palate (builds on medial maxillectomy)

Approach: Weber-Ferguson incision or sublabial

VII. Subtotal and Total Maxillectomy

Subtotal Maxillectomy

Indications: T2–T3 maxillary tumours — involving the maxillary antrum extensively, hard palate, medial orbital floor/wall, pterygoid fossa, but orbital floor preserved (if possible).

Approach: Weber-Ferguson incision with subciliary extension.

Technique:

Upper cheek flap raised; lower eyelid portion delicately elevated off orbicularis oculi
Flap taken laterally to 1 cm beyond the lateral canthus
Orbicularis oculi and orbit dissected off the inferior orbital rim in subperiosteal fashion; elevation carried back to the orbital apex
Masseter muscle attachment to inferior zygoma divided
Intraoral: mucosal incision between lateral incisor and canine → posteriorly down midline of hard palate → to the soft palate junction → laterally to the maxillary tubercle → out to the gingivobuccal sulcus behind the last molar; medial pterygoid muscle attachments cut to free the maxilla
Nasal cavity entered at the piriform recess
Osteotomies:
- Premaxilla into nasal cavity (anterior)
- Nasal process and medial orbital rim; anterior maxilla divided preserving bony orbital floor
- Zygomatic arch divided; lateral maxillary wall divided
- Freed from pterygoid plates through the hamulus using large curved osteotome
Specimen removed en bloc
Reconstruction: obturator (skin graft + Xeroform packing, prefabricated dental obturator wired to preserved dentition) or microvascular free flap

Total Maxillectomy

Indications: T3 maxillary tumours with involvement of the orbital floor; tumours of the infrastructure and suprastructure with orbital floor invasion.

Difference from subtotal: Includes the orbital floor in the resection specimen (see Fig. 94.8B in Cummings).

Technique: Same as subtotal maxillectomy with additional removal of the orbital floor. The orbital contents are retracted superiorly and the floor osteotomised and included with the specimen. The orbital periosteum (periorbita) must be assessed — if intact and not infiltrated, the globe can be preserved.

Reconstruction: Orbital floor must be reconstructed (titanium mesh, bone graft, or free flap) to prevent enophthalmos and diplopia.

VIII. Total Maxillectomy with Orbital Exenteration

Indications: T4a disease — invasion of anterior orbital contents (periorbita breached, orbital fat/muscles involved). The globe cannot be preserved once the periorbita is infiltrated.

Contraindications to globe preservation: Periorbita invasion, adherence of tumour to extraocular muscles, fat infiltration, decreased visual acuity preoperatively from tumour compression.

Technique:

Weber-Ferguson incision with standard total maxillectomy steps, then:
The eyelids are sewn together with a running suture
Circumferential skin incision made around the orbital rim; periorbita incised at the rim and dissected free of orbital walls
Optic nerve and ophthalmic vessels divided deep at the orbital apex with heavy scissors or a cutting stapler
The entire orbital contents removed en bloc with the maxillary specimen
The resulting defect is lined with a split-thickness skin graft or filled with a free flap (commonly rectus abdominis or anterolateral thigh)
The eyelid skin is fashioned into a socket lining or a prosthetic eye fitted postoperatively

IX. Craniofacial Resection (CFR)

Indications: T3–T4a disease of the ethmoid sinus and nasal cavity with cribriform plate involvement or anterior skull base extension; olfactory neuroblastoma; SNUC with intracranial extension.

CFR is the historical gold standard for skull base malignancies. Overall 5-year survival for sinonasal cancer undergoing CFR is approximately 50% — K.J. Lee's Essential Otolaryngology.

Mortality: ~4.7%; Morbidity: 33–36% (wound 20%, systemic 5%, orbital 1.5%). Risk increased with medical comorbidities, prior radiation, dural invasion, and brain invasion.

Technique:

Transcranial (neurosurgical) component: Bicoronal scalp incision; frontal craniotomy; frontal lobe retracted
The dura is inspected and, if involved, excised and reconstructed
The cribriform plate and olfactory bulbs are resected under direct intracranial vision
The anterior skull base is osteotomised
Transfacial (rhinological) component: Lateral rhinotomy, midfacial degloving, or Weber-Ferguson incision depending on tumour extent
The sinonasal portion of the tumour is mobilised from below
The specimen is delivered en bloc — nasal cavity, ethmoid complex, cribriform plate, and adherent dura if involved
Reconstruction: Pericranial flap (most commonly) turned down to reconstruct the skull base and dural defect; supported from below with Xeroform packing in the nasal cavity; scalp closed primarily

Variants of extent (Fig. 94.8C and D in Cummings):

Limited CFR: ethmoid complex + cribriform plate
Extended CFR: adds orbital exenteration and/or additional skull base
Combined with maxillectomy for maxilloethmoid tumours

X. Endoscopic Approaches

Endoscopic Partial or Medial Maxillectomy

Indications: T1–T2 nasal cavity and ethmoid tumours without orbital, palatal, anterolateral frontal sinus, or facial soft tissue extension; inverted papilloma with focal malignant transformation; select adenocarcinomas.

Absolute contraindications to endoscopic approach:

Facial or orbital soft tissue extension
Significant palatal involvement
Anterolateral frontal sinus involvement
Dural involvement beyond the mid-pupillary line
Tumours requiring en bloc resection for margin control (certain histologies)

Advantages: No facial incisions; no craniotomy; no brain retraction; excellent magnification; reduced blood loss; shorter hospitalisation; ability to identify tumour origin by gradual debulking.

Technique:

Nasoendoscopic exposure with 0° and 45° telescopes
Posterior two-thirds of nasal septum may be removed for bilateral access (intersinus septectomy)
Wide sphenoidotomy with intersinus septectomy for posterior exposure
Sequential resection: identification of tumour origin → gradual debulking → progressive exposure of surgical margins
For endoscopic medial maxillectomy: inferior turbinate removed, medial wall of maxillary sinus resected under direct vision; uncinectomy and maxillary antrostomy to achieve wide exposure
Frozen section margin assessment during resection
Skull base exposure for cribriform plate involvement via endoscopic craniofacial approach (without craniotomy for select T3 ethmoid lesions)

Endoscopic Endonasal Approach (EEA) for Skull Base

Indications: Select T3–T4a ethmoid/nasal cavity lesions with cribriform plate involvement, but without significant dural or frontal lobe involvement. Increasingly replacing CFR at experienced centres.

Advantages over CFR: No facial incisions; no frontal craniotomy; no brain retraction; equivalent oncologic outcomes reported in select series.

Key steps:

Bilateral wide sphenoidotomy and intersinus septectomy
Posterior nasal septum resected
Complete ethmoidectomy
Skull base exposed; anterior and posterior ethmoid arteries ligated
Cribriform plate and olfactory bulbs resected under endoscopic vision
Dural entry if involved; reconstruction with nasoseptal (Hadad-Bassagastellys) flap or pericranial flap via combined approach

XI. Stage-Specific Surgical Decision Framework

Maxillary Sinus

Stage	Surgical Procedure
T1	Endoscopic medial maxillectomy (if medial wall); or Caldwell-Luc/sublabial for small anteroinferior lesions
T2	Open medial maxillectomy via lateral rhinotomy; or infrastructural maxillectomy (alveolus/hard palate involvement)
T3	Subtotal maxillectomy (Weber-Ferguson ± subciliary) preserving orbital floor if possible; or total maxillectomy if orbital floor is involved. Consider CFR if ethmoid/cribriform involved
T4a	Total maxillectomy + orbital exenteration for anterior orbital content invasion; ± craniofacial resection for skull base/anterior cranial fossa extension
T4b	Generally considered unresectable (orbital apex, dura with brain invasion, clivus, carotid involvement); primary chemoradiation or induction chemotherapy → reassess resectability

Nasal Cavity

Stage	Surgical Procedure
T1	Endoscopic resection (partial endoscopic ethmoidectomy or nasal resection); lateral rhinotomy for anterior lesions
T2	Open medial maxillectomy or extended endoscopic resection depending on subsite involvement
T3	Medial maxillectomy + orbital floor/medial wall resection; or combined endoscopic-open approach for cribriform involvement
T4a	Craniofacial resection ± orbital exenteration
T4b	Unresectable; chemoradiation ± palliative surgery

Ethmoid Sinus

Stage	Surgical Procedure
T1	Endoscopic total ethmoidectomy
T2	Extended endoscopic ethmoidectomy ± medial maxillectomy
T3	CFR (limited: ethmoid + cribriform plate) or endoscopic endonasal skull base resection at experienced centres; medial orbital wall resection if orbital invasion present
T4a	CFR with orbital exenteration for anterior orbital contents involvement; extended endoscopic approach at expert centres
T4b	Unresectable; chemoradiation primary

XII. Neck Management

Regional lymph node metastasis is uncommon at presentation (10–30%) but cervical failure contributes significantly to poor outcomes.
Elective neck dissection or irradiation is indicated for:
- High-risk histologies (SCC, undifferentiated carcinoma)
- T3–T4 primary tumours
- Ipsilateral levels I–III are most commonly at risk
Therapeutic neck dissection for clinically positive nodes (selective or comprehensive depending on burden)

XIII. Reconstruction

Brown-Shaw Classification (Maxillectomy Defects)

Vertical (numbered I–VI): I = no oronasal fistula → IV = orbital exenteration → V = orbitomaxillary → VI = nasomaxillary

Horizontal (lettered A–D): A = palate only → D = >half maxillectomy

Reconstruction Options by Defect

Defect Class	Reconstruction
I–IIb (≤half lateral alveolus and palate)	Obturator OR radial forearm fasciocutaneous free flap
III (orbital support needed)	Fibula free flap (bone + soft tissue) or scapular free flap
IV (with orbital exenteration)	Rectus abdominis or anterolateral thigh (ALT) free flap; prosthetic eye
Skull base	Pericranial flap (CFR) or nasoseptal (Hadad) flap (endoscopic)

Microvascular free flap reconstruction has become standard for complex maxillectomy defects: it better restores facial contour, supports the orbital floor, accepts dental implants, and withstands postoperative radiation effects. Speech intelligibility and swallowing outcomes are generally superior to obturation for defects involving more than 50% of the palate.

XIV. Special Considerations

Orbital Preservation

The key decision in T3–T4 disease is whether to preserve the orbit. Indications for exenteration:

Periorbita breached with tumour infiltration of orbital fat
Extraocular muscle or optic nerve involvement
Decreased preoperative visual acuity

If the periorbita (orbital periosteum) is intact despite bony destruction of the orbital walls, the globe is typically preserved and postoperative radiation covers residual microscopic disease.

Perineural Invasion (PNI)

The most commonly affected nerves are V2 (maxillary), hypoglossal, V3, and facial nerve. PNI mandates wider resection along the nerve and tracking back to the Gasserian ganglion when V2/V3 are involved. MRI findings (widened neural foramina, enhancement, loss of fat planes) guide resection extent.

Unresectability Criteria

A tumour is generally considered unresectable if it involves:

Bilateral orbital apex involvement (bilateral blindness)
Brain parenchyma with involvement beyond the dura in non-eloquent cortex
Carotid artery encasement
Clivus or nasopharyngeal prevertebral muscles (implies prevertebral fascia fixation)
Bilateral cavernous sinus involvement

Summary

The surgical management of sinonasal malignancies is guided principally by anatomical extent (T stage), with the spectrum ranging from limited endoscopic resection for T1 disease to craniofacial resection with orbital exenteration for advanced T4a disease. T4b disease is generally unresectable and managed primarily with chemoradiation. The preferred overall approach for resectable sinonasal cancer remains complete surgical resection followed by postoperative radiotherapy, with chemotherapy added for high-risk histologies and advanced stages. At experienced centres, endoscopic endonasal approaches increasingly replace open CFR for select T3 ethmoid and nasal cavity tumours, offering equivalent oncological results with substantially reduced morbidity.

Sources: Cummings Otolaryngology Head and Neck Surgery, 7th ed. (Chapter 94, pp. 1735–1760); K.J. Lee's Essential Otolaryngology, 10th ed. (pp. 593–600)

Create pdf

Running Command

Writing File

Running Command

Your PDF is ready:

Sinonasal Surgery TNM

PDF Document · PDF

The document covers all 15 sections across ~6 pages with full formatting:

TNM staging tables for maxillary sinus, nasal cavity, and ethmoid sinus (AJCC 8th ed.)
Open vs. endoscopic comparison table
Step-by-step surgical techniques — Caldwell-Luc, lateral rhinotomy, medial maxillectomy, infrastructural/subtotal/total maxillectomy, orbital exenteration, craniofacial resection, and endoscopic EEA
Stage-specific decision tables for each subsite
Reconstruction guide (Brown-Shaw classification)
Unresectability criteria, orbital preservation decision points, and PNI management
Summary at-a-glance table and references

This is a shared conversation. Sign in to Orris to start your own chat.